药物靶点与经济价值——基于2000～2009年美国上市新药的实证研究

摘要

目的:分析药物靶点与经济价值的关系,揭示高经济价值药物的技术特征,为经济高效的新药开发提供参考.方法:运用Drugs@ FDA收集2000～2009年FDA批准上市的NME药物通用名,通过Drugbank和IMShealth数据库收集样本药物靶点数和销售额的数据,运用SPSS做统计描述和推论.结果:靶点数与销售额有十分显著的相关性(Pearson相关系数为0.215,P＜0.05),年销售额超过10亿美元的畅销药的平均靶点数为3.9,远高于2.5的样本平均水平.结论:从近I0年上市新药的数据来看,多靶点药物相对而言具有更高的经济价值,这可能是由于药物靶点与治疗效果、适应症和疾病复杂性等的关系导致的.%Objective; To analyze the relationship between drug targets and economic value, and to explore technological feature of drugs with high economic value. Methods: To retrieve FDA approved NME drugs between 2000-2009 as samples by using Drugs @ FDA database, to collect target number and sales of sampling drugs by using Drugbank and IMS health databases, and to conduct statistical description and inference by SPSS. Result: The number of drug targets is significantly correlated with sales (Pearson correlation coefficient was 0. 215, P <0. 05). The average target number of blockbuster drugs is 3.9, which is much higher than the average of sample 2. 5. Conclusion; Drugs which have more targets tend to have higher sales. This kind of relationship is perhaps caused by the association between drug target and drug efficacy, indications, and complex diseases etc.